Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization -215% Improvement Relative Risk Symptomatic case -40% Case -5% c19hcq.org Oztas et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 650 patients in Turkey Higher hospitalization (p=0.36) and more symptomatic cases (p=0.44), not stat. sig. Oztas et al., J. Medical Virology, doi:10.1002/jmv.27731 Favors HCQ Favors control
Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine
Oztas et al., Journal of Medical Virology, doi:10.1002/jmv.27731
Oztas et al., Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with.., Journal of Medical Virology, doi:10.1002/jmv.27731
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 317 HCQ users and 333 household contacts, showing higher risk with HCQ.
Authors do not adjust for the very different baseline risk for systemic autoimmune disease patients. Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [Ferri]. This study is excluded in the after exclusion results of meta analysis: not adjusting for the different baseline risk of systemic autoimmune patients; excessive unadjusted differences between groups.
risk of hospitalization, 215.1% higher, RR 3.15, p = 0.36, treatment 3 of 317 (0.9%), control 1 of 333 (0.3%).
risk of symptomatic case, 40.1% higher, RR 1.40, p = 0.44, treatment 16 of 317 (5.0%), control 12 of 333 (3.6%).
risk of case, 5.0% higher, RR 1.05, p = 0.88, treatment 22 of 317 (6.9%), control 22 of 333 (6.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Oztas et al., 21 Mar 2022, retrospective, Turkey, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Sarvan Aghamuradov ORCID iD: 0000-0002-7196-0098 Serdal Ugurlu ORCID iD: 0000-0002-9561-2282 Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine Mert Oztas1(Orcid ID: 0000-0002-4077-1374), Murat Bektas2(Orcid ID: 0000-0002- Accepted Article 1788-3837), Ilker Karacan3 (Orcid ID: 0000-0003-3100-0866), Numune Aliyeva2(Orcid ID: 0000-0003-2848-4396), Ayten Dag1 (Orcid ID: 0000-0003-3157531X), Sarvan Aghamuradov2(Orcid ID: 0000-0002-7196-0098), Selim Berke Cevirgen1 (Orcid ID: 0000-0002-7099-4827), Selma Sari2 (Orcid ID: 0000-00016839-8164), Murat Bolayirli4 (Orcid ID: 0000-0001-5755-7860),Gunay Can5 (00000001-5815-6700), Gulen Hatemi1 (0000-0002-1952-1135), Emire Seyahi1 (00000003-4965-2918),Huri Ozdogan1 (Orcid ID: 0000-0003-4632-8258), Ahmet Gul2 (Orcid ID: 0000-0001-8219-3720), Serdal Ugurlu1 (Orcid ID: 0000-0002-9561-2282) 1- Istanbul University-Cerrahpasa, Department of Medicine, Division of Rheumatology, Istanbul, Turkey 2- Istanbul University, Department of Medicine, Division of Rheumatology, Istanbul, Turkey 3- Istanbul Medeniyet University,Department of Molecular Biology and Genetics, Istanbul, Turkey 4- Istanbul University-Cerrahpasa, Department of Medical Biochemistry, Istanbul, Turkey 5- Istanbul University-Cerrahpasa, Department of Public Health, Istanbul, Turkey Corresponding Author: Serdal Ugurlu (MD) Rheumatology Department, Istanbul University Cerrahpasa, Istanbul, Turkey Cell Phone no: 02124143000 E-mail: serdalugurlu@gmail.com Word Count: 1535 Declarations Funding This study was supported by Department of Scientific Research Projects,Istanbul University-Cerrahpasa (Grant number:34919) Conflict of Intersest Statement No conflict of interest declared Ethics approval This study was approved by Istanbul University-Cerrahpasa Ethics Comitee (14.05.2020-62050). This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.27731. This article is protected by copyright. All rights reserved. Accepted Article All authors were involved in drafting the article or revising it, and all authors approved the final version to be published. Dr. Ugurlu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design. Mert Oztas, Murat Bektas, Ilker Karacan, Numune Aliyeva, Ayten Dag, Sarvan Aghamuradov, Selim Berke Cevirgen, Selma Sari, Murat Bolayirli, Gunay Can, Huri Ozdogan, Ahmet Gul, Serdal Ugurlu Acquisition of data. Mert Oztas, Murat Bektas, Numune Aliyeva, Ayten Dag, Sarvan Aghamuradov, Selim Berke Cevirgen, Selma Sari, Murat Bolayirli Analysis and interpretation of data. Mert Oztas, Murat Bektas Gunay Can,, Huri Ozdogan, Ahmet Gul, Serdal Ugurlu Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Consent for Publication We hereby confirm that this article has not been published and is not under consideration for publication elsewhere. All authors have contributed to, seen, and approved the final, submitted version of the manuscript. Consent to Participate Written..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit